disitamab vedotin + tislelizumab + bevacizumab

This is a combination regimen consisting of three agents with distinct but complementary mechanisms of action, primarily under investigation for cancer therapy. **Disitamab vedotin** is an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2). It consists of a humanized anti-HER2 monoclonal antibody (disitamab) linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon binding to HER2-expressing tumor cells, it is internalized and releases MMAE intracellularly, disrupting microtubules and inducing cell death[1][3][4]. **Tislelizumab** is a humanized IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1/PD-L2 and thereby enhancing T-cell mediated antitumor immunity[8]. **Bevacizumab** is a recombinant humanized monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis by preventing VEGF from interacting with its receptors on endothelial cells. This reduces tumor blood supply and growth[6][9]. The rationale for combining these agents lies in their non-redundant mechanisms—targeted cytotoxicity against HER2+ cells, immune checkpoint inhibition to enhance antitumor immunity, and antiangiogenic effects to starve tumors of blood supply—which may result in synergistic anticancer activity.

Brand names

Baizean